WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Grand Rounds, Inc.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
FierceBiotech | February 12, 2020
ALX Oncology has raised $105 million. The series C round will support phase 2 trials of CD47 myeloid checkpoint inhibitor ALX148 in combination with other anti-cancer therapies. Multiple drug developers have gone after CD47 since evidence of its role in the interactions between cancer cells and the immune system became clear. The evidence suggested tumors evade immune attacks by upregulating CD47, leading researchers to posit that blocking the signal will expose cancer cells to a full-force offe...
Industrial Impact
BioAuxilium Research Inc. | February 10, 2022
At the annual Society for Laboratory Automation and Screening International Conference and Exhibition in Boston, BioAuxilium Research Inc., a biotech tool company focused on facilitating access to fully validated assay kits to the biomedical research community, today announced the expansion of its no-wash THUNDER™ time-resolved Förster resonance energy transfer technology portfolio by introducing new cell signaling pathway and biomarker research assay kits, along with a panel of &ldqu...
FN Media Group | May 08, 2020
The biotech boom is back. After its big breakthrough a few years ago, the biotech industry fell silent. Now, it is in the spotlight once again as smart money races in to back some once-in-a-generation breakthroughs. Mentioned in today's commentary includes: CRISPR Therapeutics AG (NASDAQ: CRSP), Sangamo Therapeutics, Inc. (NASDAQ: SGMO), Microsoft Corporation (NASDAQ: MSFT), International Business Machines Corporation (NYSE: IBM), Apple Inc. (NASDAQ: AAPL).From exciti...
MedTech
Salipro Biotech | February 09, 2022
Swedish biotech company Salipro Biotech AB announced that the European Patent Office has granted a further European Patent to the company, No. EP 3 043 814 B1 entitled "Antigen and method for production thereof", following the approval of the US-member of this patent family already in 2018 under US Patent 10,159,729 B2. The patents cover the composition-of-matter, methods and uses of the company's novel antigen technology, strengthening Salipro Biotech's proprietary platform te...
Whitepaper
Cell and Gene Therapy, Industrial Impact
Industrial Impact, Medical
Cell and Gene Therapy, MedTech
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE